0001836268-20-000005.txt : 20201218
0001836268-20-000005.hdr.sgml : 20201218
20201217182139
ACCESSION NUMBER: 0001836268-20-000005
CONFORMED SUBMISSION TYPE: D/A
PUBLIC DOCUMENT COUNT: 1
ITEM INFORMATION: 06b
FILED AS OF DATE: 20201218
DATE AS OF CHANGE: 20201217
EFFECTIVENESS DATE: 20201218
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: MitoChem Therapeutics, Inc.
CENTRAL INDEX KEY: 0001836268
IRS NUMBER: 453845208
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: D/A
SEC ACT: 1933 Act
SEC FILE NUMBER: 021-383566
FILM NUMBER: 201397364
BUSINESS ADDRESS:
STREET 1: 645 MEETING STREET
CITY: CHARLESTON
STATE: SC
ZIP: 29403
BUSINESS PHONE: 520-204-5552
MAIL ADDRESS:
STREET 1: 645 MEETING STREET
CITY: CHARLESTON
STATE: SC
ZIP: 29403
D/A
1
primary_doc.xml
X0708
D/A
LIVE
0001836268
MitoChem Therapeutics, Inc.
645 MEETING STREET
CHARLESTON
SC
SOUTH CAROLINA
29403
520-204-5552
DELAWARE
None
None
Corporation
true
Michael
Voevodsky
c/o MitoChem Therapeutics, Inc.
645 Meeting Street
Charleston
SC
SOUTH CAROLINA
29403
Executive Officer
Director
Rick
G.
Schnellman
c/o MitoChem Therapeutics, Inc.
645 Meeting Street
Charleston
SC
SOUTH CAROLINA
29403
Director
Baerbel
Rohrer
c/o MitoChem Therapeutics, Inc.
645 Meeting Street
Charleston
SC
SOUTH CAROLINA
29403
Director
Gyda
Caren
Beeson
c/o MitoChem Therapeutics, Inc.
645 Meeting Street
Charleston
SC
SOUTH CAROLINA
29403
Director
Biotechnology
Decline to Disclose
- 06b
true
0001836268-20-000002
2020-12-02
false
true
false
0
300000
235766
64234
false
7
0
0
0
Other than the payment of salaries and other compensation and benefits and reimbursement of expenses, no officer, director, partner, manager or promoter will receive any payments from the proceeds of this offering.
false
MitoChem Therapeutics, Inc.
/s/ Michael Voevodsky
Michael Voevodsky
President and Chief Executive Officer
2020-12-17